Sotorasib is approved in the United States to treat KRAS p.G12C–mutated non–small-cell lung cancer. Its efficacy and safety in KRAS p.G12C–mutated pancreatic cancer have been unknown. New research findings are summarized in a short video. https://nej.md/3GfOXNp | The New England Journal of Medicine

What does a RAS mutation mean, and what is a KRAS biomarker? Watch the video to learn more about this gene, and visit our website to learn about when and how you should have biomarker testing for a RAS gene, the treatment options if you have a mutation, and what to ask your doctor: bit.ly/BiomarkerKRAS Special thanks to Amgen for supporting the development of this educational material. | Colorectal Cancer Alliance